Surgical ablation of the right greater splanchnic nerve for the treatment of heart failure with preserved ejection fraction: First‐in‐human clinical trial

2021 ◽  
Author(s):  
Filip Málek ◽  
Piotr Gajewski ◽  
Robert Zymliński ◽  
Dariusz Janczak ◽  
Mariusz Chabowski ◽  
...  
Keyword(s):  
Heart Failure ◽  
Clinical Trial ◽  
Ejection Fraction ◽  
Splanchnic Nerve ◽  
Preserved Ejection Fraction ◽  
Human Clinical Trial ◽  
Surgical Ablation ◽  
Greater Splanchnic Nerve ◽  
The Right

Endovascular Ablation of the Right Greater Splanchnic Nerve for the Treatment of Heart Failure with Preserved Ejection Fraction - First-in-human Clinical Trial

2020 ◽  
Vol 26 (12) ◽  
pp. 1110-1111
Author(s):  
Sanjiv J. Shah ◽  
Teona Zirakashvili ◽  
Nikoloz Shaburishvili ◽  
Giorgi Shaishmelashvili ◽  
Horst Sievert ◽  
...  
Keyword(s):  
Heart Failure ◽  
Clinical Trial ◽  
Ejection Fraction ◽  
Splanchnic Nerve ◽  
Preserved Ejection Fraction ◽  
Human Clinical Trial ◽  
Greater Splanchnic Nerve ◽  
The Right

Greater Splanchnic Nerve Stimulation in Heart Failure With Preserved Ejection Fraction

2021 ◽  
Vol 77 (15) ◽  
pp. 1952-1953
Author(s):  
Marat Fudim ◽  
Petr Neuzil ◽  
Filip Malek ◽  
Zoar J. Engelman ◽  
Vivek Y. Reddy
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Nerve Stimulation ◽  
Splanchnic Nerve ◽  
Preserved Ejection Fraction ◽  
Greater Splanchnic Nerve ◽  
Splanchnic Nerve Stimulation

Right Heart Phenotype in Heart Failure With Preserved Ejection Fraction

2021 ◽  
Author(s):  
Marco Guazzi ◽  
Robert Naeije
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Right Ventricular ◽  
Ventricular Dysfunction ◽  
Imaging Techniques ◽  
Treatment Options ◽  
Right Ventricular Dysfunction ◽  
Preserved Ejection Fraction ◽  
Right Heart ◽  
The Right

The health burden of heart failure with preserved ejection fraction is increasingly recognized. Despite improvements in diagnostic algorithms and established knowledge on the clinical trajectory, effective treatment options for heart failure with preserved ejection fraction remain limited, mainly because of the high mechanistic heterogeneity. Diagnostic scores, big data, and phenomapping categorization are proposed as key steps needed for progress. In the meantime, advancements in imaging techniques combined to high-fidelity pressure signaling analysis have uncovered right ventricular dysfunction as a mediator of heart failure with preserved ejection fraction progression and as major independent determinant of poor outcome. This review summarizes the current understanding of the pathophysiology of right ventricular dysfunction in heart failure with preserved ejection fraction covering the different right heart phenotypes and offering perspectives on new treatments targeting the right ventricle in its function and geometry.

scholarly journals APPLICATION OF THE H2FPEF-SCORE TO A GLOBAL CLINICAL TRIAL OF PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION: THE TOPCAT TRIAL

2019 ◽  
Vol 73 (9) ◽  
pp. 912
Author(s):  
Peder Myhre ◽  
Muthiah Vaduganathan ◽  
Brian Claggett ◽  
Carolyn Lam ◽  
Akshay Desai ◽  
...  
Keyword(s):  
Heart Failure ◽  
Clinical Trial ◽  
Ejection Fraction ◽  
Preserved Ejection Fraction ◽  
Patients With Heart Failure ◽  
Global Clinical Trial

Abstract 17235: Comparision of Outcomes in Patients Undergoing Catheter versus Surgical Ablation for Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction

Circulation ◽  
2020 ◽  
Vol 142 (Suppl_3) ◽  
Author(s):  
Krunalkumar Patel ◽  
Kirtenkumar Patel ◽  
Jay Shah ◽  
Rajkumar Doshi ◽  
Amitkumar Patel ◽  
...  
Keyword(s):  
Heart Failure ◽  
Atrial Fibrillation ◽  
Ejection Fraction ◽  
Hospital Mortality ◽  
Clinical Outcomes ◽  
Length Of Hospital Stay ◽  
Cardiac Complications ◽  
P Value ◽  
Preserved Ejection Fraction ◽  
Surgical Ablation

Introduction: There is a lack of research comparing outcomes of Surgical Ablation (SA) and Catheter Ablation (CA) among Atrial Fibrillation(AF) patients with heart failure with Preserved Ejection Fraction (HFpEF) and . Hypothesis: The main objective is to compare short-term clinical outcomes of SA and CA in AF patients with HFpEF. Methods: We used the national inpatient sample to identify patients over 18 years with HFpEF hospitalization and AF, and undergoing SA and CA from 2016 - 2017. The clinical outcomes of SA versus CA in AF stratified as non-paroxysmal and paroxysmal were analyzed. Results: 1,530 HFpEF hospitalizations with AF who underwent SA and 1,045 HFpEF hospitalizations with AF who underwent CA were included in the analysis. Patients undergoing CA had higher baseline comorbidity. The in-hospital mortality between HFpEF with AF undergoing SA as compared to CA was similar (1.9% versus 1.4%, adjusted P-value 0.04). Patients undergoing SA had a significantly longer length of hospital stay, a higher percentage of post-procedural, and cardiac complications. In HFpEF patients with non-paroxysmal AF, SA as opposed to CA was associated with a higher percentage of in-hospital mortality (2.7% versus 0%, adjusted P-value=0.23), a longer length of stay, a higher cost of treatment, and a higher percentage of cardiac complications. Conclusions: In conclusion, CA is associated with lower in-hospital outcomes as compared to SA among AF with HFpEF patients. Further research with freedom from AF is needed between this group with long-term out c omes.

The right heart in heart failure with preserved ejection fraction: insights from cardiac magnetic resonance imaging and invasive haemodynamics

2015 ◽  
Vol 18 (1) ◽  
pp. 71-80 ◽  
Author(s):  
Stefan Aschauer ◽  
Andreas A. Kammerlander ◽  
Caroline Zotter-Tufaro ◽  
Robin Ristl ◽  
Stefan Pfaffenberger ◽  
...  
Keyword(s):  
Magnetic Resonance Imaging ◽  
Heart Failure ◽  
Cardiac Magnetic Resonance ◽  
Magnetic Resonance ◽  
Ejection Fraction ◽  
Cardiac Magnetic Resonance Imaging ◽  
Preserved Ejection Fraction ◽  
Resonance Imaging ◽  
Right Heart ◽  
The Right

scholarly journals Towards tailoring blood pressure control in HFpEF: Lessons from OPTIMIZE-HF

2019 ◽  
Vol 2019 (1) ◽  
Author(s):  
Mohamed Hassan
Keyword(s):  
Heart Failure ◽  
Atrial Fibrillation ◽  
Blood Pressure ◽  
Clinical Trial ◽  
Ejection Fraction ◽  
Observational Studies ◽  
Pressure Control ◽  
Preserved Ejection Fraction ◽  
Reduced Ejection Fraction ◽  
Over Time

[first paragraph of article]Heart failure (HF) with preserved ejection fraction (HFpEF) represents approximately 50% of the world's HF population, and this proportion is increasing over time. The diagnosis of HFpEF is more challenging than HF with reduced ejection fraction (HFrEF). Patients with HFpEF are significantly older, more likely to be female, and more likely to have hypertension, obesity, anemia, atrial fibrillation, renal disease, and pulmonary disease compared to those with HFrEF. In observational studies, rates of hospitalization and death among patients with HFpEF approach those with HFrEF, however in clinical trial populations, outcomes are better in patients who have HFpEF. Death from non- cardiovascular causes is more common in patients who have HFpEF than in those with HFrEF, and a smaller percentage of patients with HFpEF die from CVD-related causes.

scholarly journals PATHOPHYSIOLOGIC PREDICTORS OF ADVERSE OUTCOMES IN HEART FAILURE WITH PRESERVED EJECTION FRACTION: IMPORTANCE OF THE RIGHT VENTRICLE

2011 ◽  
Vol 57 (14) ◽  
pp. E399
Author(s):  
Michael A. Burke ◽  
Venkatesh Anjan ◽  
Deepak Gupta ◽  
Justin Fox ◽  
Sudarsana Chakrabarti ◽  
...  
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Right Ventricle ◽  
Adverse Outcomes ◽  
Preserved Ejection Fraction ◽  
The Right
Sign in / Sign up

Export Citation Format

Share Document